Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying
WASHINGTON — Purdue Pharma, the embattled opioid maker, has quietly split ways with PhRMA, the powerful lobbying organization charged with representing the drug industry in Washington.
The break is the latest demonstration that the drug maker, which has filed for bankruptcy and is inundated by lawsuits across the country for its role in marketing OxyContin, is retreating from attempts to influence federal drug policy or restore its reputation.
